TB Drugs: Rifampin

May 8, 2026

Upload by Patrick

This document provides an in-depth overview of Rifampin, a critical medication used in the treatment of Tuberculosis (TB) and Leprosy, also known as Hansen's disease. The primary focus is on its mechanism of action as a potent bacteriostatic agent that inhibits bacterial cell wall synthesis. The text highlights that while many antitubercular drugs are bacteriostatic, Rifampin, along with isoniazid and streptomycin, exhibits bactericidal activity, making it a crucial component in therapeutic protocols. The document meticulously details the diagnostic indications and common adverse reactions associated with Rifampin use, including nausea, vomiting, gastrointestinal distress, fatigue, vertigo, rash, and the characteristic reddish-orange discoloration of bodily fluids. It also addresses potential hematologic changes and renal insufficiency, referencing specific clinical guidelines (Ford 106). Furthermore, the contraindications and precautions for Rifampin usage are clearly delineated, emphasizing its use with caution during pregnancy (category C) and lactation, and in patients with compromised hepatic or renal function. A significant portion of the document is dedicated to the nursing alert concerning Leprosy, explaining its etiology by Mycobacterium leprae, its chronic and communicable nature, and its historical context. The impact on peripheral nerves, leading to sensory loss and muscle weakness, is described, along with the traditional fear associated with skin manifestations. The document concludes by listing the current therapeutic agents for Leprosy, including Dapsone, Clofazimine (Lamprene), Rifampin (Rifadin), and Ethionamide (Trecator), reinforcing Rifampin's dual role in combating these significant infectious diseases.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

May 8, 2026

Upload by Patrick